Anavex Life Sciences Corporation (AVXL) Company Profile & Statistics

Anavex Life Sciences Corporation
AVXL
(Nasdaq - US)
N/A
6.75
-0.09 (-1.39%)
in:usd•As of: Jul 26, 2024 15:59 UTC -4
Open
6.92
High
7.24
Low
6.73

About Anavex Life Sciences Corporation

CEO

Christopher Missling

Headquarters

630 5th avenue, 20th floor

new york, ny 10111, united states

Auditor

GRANT THORNTON LLP

Employees

Share Holders

Website

www.anavex.com

Industry

biotechnology

Sector

health technology

Company Overview

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways.

Anavex Life Sciences Corporation Statistics

Valuation Measures

Market Capitalization ²	570.90M
Enterprise Value	431.51M
Enterprise Value/EBITDA (ttm)	-8.63
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	3.93
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	0.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	0.00%
Return on Equity (ttm)	-29.04%
Return on Invested Capital (ttm)	-29.01%
Return on Assets (ttm)	-26.85%

Income Statement

Revenue (ttm)	0.00
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	0.00
EBITDA (ttm)³	-49.99M
Net Income Avi to Common (ttm)	-40.59M
Diluted EPS (ttm)	-0.50

Share Statistics

Beta (5Y Monthly)	0.63
52-Week Change	-15.58%
S&P500 52-Week Change	19.54%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	84.64M
Dividend Yield	0.00%
Float ⁴	75.33M
% Held by Insiders	11.00%
% Held by Institutions	31.55%

Balance Sheet

Total Cash (mrq)	139.39M
Total Cash Per Share (mrq)	1.65
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	15.12%
Quick Ratio (mrq)	15.12%
Book Value Per Share (mrq)	1.61

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.23
Free Cash Flow (ytd)	-18.97M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Anavex Life Sciences Corporation

Trade With A Regulated Broker